Study shows noninferior overall survival with active surveillance compared with surgery in some oesophageal cancers
Findings from the SANO trial also reported clinically complete responses after neoadjuvant chemoradiotherapy
Study data show a significant benefit of neoadjuvant immunotherapy in HR-positive early breast cancer for the first time
Efficacy of PD-1 inhibitors in this setting reflects that reported in triple-negative breast cancer and is confirmed by long-term data presented at the ESMO Congress
TIL therapy – an opportunity for a few centres?
Regulatory, practical and economic challenges are associated with implementing this personalised treatment on a larger scale, thus currently limiting its availability and accessibility to patients
Guiding you through the latest cancer research
At the ESMO Congress 2023, our mission with the newspaper articles and expert opinions is to disseminate clear information from the studies presented and help understand their potential impact on cancer care
Clonal haematopoiesis in the tumour microenvironment is an indicator of poor prognosis in NSCLC
Results from the TRACERx study suggest a potential role of CHIP as a prognostic biomarker, but further research is needed
Single-cell DNA sequencing confirms considerable intratumoural heterogeneity in breast cancer
The study involved patients with HR-positive/HER2-negative localised disease, but additional analyses are required to describe implications for clinical practice.
Complete molecular characterisation is feasible for many cancer patients, study suggests
In the MATCH-R study, comprehensive profiling included successful sequencing of DNA and also of RNA, enabling the detection of actionable genomic alterations
Precision oncology – are we at an inflection point?
At Molecular Analysis for Precision Oncology (MAP) Congress 2023, international experts discuss the future of histology-agnostic drug development and clinical trial design
Liquid biopsy in colorectal cancer – the time has come?
Recent findings from studies confirm the promises of ctDNA in this setting, but unanswered questions still remain about timing and methodology
Advanced genetic testing is largely inaccessible to cancer patients across Europe
An ESMO study shows that precision oncology is out of reach for the majority of patients, with costs of technologies and reimbursement policies acting as major barriers